Technicals Stability Returns

Fundamental Analysis of Glaxosmithkline Pharmaceuticals (GLAXO)

Summary    Balance Sheet    Cash Flow    Income    Qtrly Income    Valuation Ratio    Profitability Ratios    Solvency    Efficiency Ratios    

Guru Numbers
Book Value/Share157.20
EV/EBITDA32.93
Market Cap (Cr)21092.74
Enterprise Value (Cr)20819.00
Piotroski F-Score6.00
Altman Z Score8.97
Graham No592.63
Price/ Graham 2.10
Peter Lynch Ratio29.77
Sloan Ratio0.278
Peter Lynch Fair value950.09
Price/ Peter Lynch FV1.31
TSR Fair value758.58
Key Financial ratios of GLAXO
Ratio Latest FY Yoy Change TTM MRQ Screener/
About
Price to Earning    16.66 -75.55 % 12.54    
Price to Book    10.60 -35.78 % 10.07 14.49    
Price to Sales    8.61 3.26 % 6.42    
Earning Per Share    100.04 373.23 % 99.30 11.42    
Return On Equity    63.64 162.68 % 89.74 13.29    
Return On Asset    36.58 218.09 % 45.73 6.41    
Net Profit Margin    51.70 322.31 % 51.17 21.10    
Operating Profit Margin    21.10 19.64 % 23.06 28.02    
EBITDA Margin    25.91 41.37 % 26.44 30.42    
Debt to Equity Ratio    0.0047 -51.93 % 0.0099    
Current Ratio    2.18 34.26 % 1.69    
Quick Ratio    1.87 52.84 % 1.20    
View Historitcal ratios of Glaxosmithkline Pharmaceuticals Ltd.
Valuation Ratios   Profitability Ratio   Solvency Ratios   Efficiency Ratios
Screen Financial Ratio using Custom Screener
Terrific View
Tsr Profitability Index - Excellent Score of 84.38
Tsr Stability Index - Excellent Score of 89.06
Altman Z Score of 8.97 suggests good Stability
Earning Yield of 8.03 %
YoY Net Margin Jump by 322.31%
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 89.74%
During the past twelve months, the company has given a strong Return On Asset of 45.73%
During the past twelve months, the company has given a strong Net Margin of 51.17%
All key Trailing Twelve Months Margin growing by 15 %
Steady View
Annual sales of the company is increased for three years in a row
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Company financial liquidity has improved
Book Value in last 3 years is trending up
Good Return On Capital Employed of 14.30
Risky View
Tsr Growth Index - Poor Score of 34.44
Price Very close to One year Low made on 03-Feb-23
Stock Returns is less than Nifty returns for consequitive last three years
Price to Book Ratio of 7.92 suggesting that it is very expensive
Terrific Steady Risky Stock View - Fundamental Snapshot
Share Overview
Promoter Owned75.00 %
Institution Owned12.70 %
Public/Others12.30 %
Outstanding Shares16.94 Cr
Floating Shares4.11 Cr
Floating / Outstanding24.24%
Book Value/Share157.20
Face value10.00
Share Holding
Annual Key Income Statement of GLAXO
Period 31_Mar_2022 31_Mar_2021 Growth
Net Income From Continuing Ops 380.77 287.27 32.55 %
Net Income 1694.72 358.15 373.19 %
Operating Income 691.70 516.00 34.05 %
Total Revenue 3278.03 2925.60 12.05 %
Operating Expense 2586.33 2409.60 7.33 %
Interest Expense 2.00 3.53 43.34 %
Tax Expense 398.28 166.72 138.89 %
Income Before tax 779.05 453.99 71.60 %
Gross Profit 1921.84 1804.19 6.52 %
Dividend Paid -506.63 -677.62 25.23 %
   
Quarterly Key Income Statement of GLAXO
Period 30_Sep_2022 30_Jun_2022 Growth
Net Income From Continuing Ops 193.42 116.23 66.41 %
Net Income 193.42 119.28 62.16 %
Operating Income 256.93 133.10 93.04 %
Total Revenue 916.87 745.10 23.05 %
Operating Expense 659.94 612.00 7.83 %
Interest Expense 0.390 0.680 42.65 %
Tax Expense 68.73 43.80 56.92 %
Income Before tax 262.15 160.03 63.81 %
Gross Profit 551.77 458.20 20.42 %
Dividend Paid 0 0 %
   
Key Balance Sheet Fields
Period 31_Mar_2022 31-Mar-21 Growth
Common Stock 169.41 169.41 0 %
Current Liabilities 1698.43 1354.58 25.38 %
Total Liabilities 1970.32 1636.39 20.41 %
Current Assets 3708.03 2202.64 68.34 %
Total Assets 4633.28 3114.65 48.76 %
Working capital 2009.60 848.06 136.96 %
Accounts Payable 570.55 466.13 22.40 %
Inventory 534.70 546.70 2.19 %
Net Receivable 205.24 215.60 4.81 %
   
Key Cash Flow Fields
Period 31_Mar_2022 31_Mar_2021 Growth
Cash EPS 26.50 21.60 22.69 %
Cash From Investment Activity -405.51 418.59 196.88 %
Cash From Financial Activity -524.24 -696.14 24.69 %
Cash Operational Activity 810.75 577.93 40.29 %
Net Cash Flow -119.00 300.38 139.62 %
NetIncome 1694.72 358.15 373.19 %
Capital Expenditure 34.64 44.23 21.68 %
Change To Inventory 12.00 -46.79 125.65 %
   



   About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Address : GSK House, Mumbai, India, 400030

URL : https://india-pharma.gsk.com

Employee Count : 3840

About TSR TECH Strength / Valuation / Growth

TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick

TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential

TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value

This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback

We are working on fundamental strength also. Please share your views to help shape up the requirement.